Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.48 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27822172 | 0.90 | PTGDR2 (0.55) | PTGDR2PPARG | |
| SCHEMBL711116 | 0.84 | PTGDR2 (0.41) | PTGDR2LMNADHODH | |
| SCHEMBL27841427 | 0.83 | ALDH1A1 (0.46) | PTGDR2PLA2G2ALMNAHPGDDHODH | |
| SCHEMBL709966 | 0.83 | PLA2G2A (0.46) | PTGDR2PLA2G2AALDH1A1 | |
| SCHEMBL708470 | 0.82 | PLA2G2A (0.51) | PLA2G2ALMNAHPGDDHODHALDH1A1 | |
| SCHEMBL709478 | 0.82 | SMN1; SMN2 (0.40) | PTGDR2LMNADHODH | |
| SCHEMBL2176856 | 0.81 | MRGPRX4 (0.43) | PLA2G2ALMNADHODH | |
| SCHEMBL28085585 | 0.79 | FFAR4 (0.49) | LMNA | |
| SCHEMBL14952247 | 0.79 | PTGDR2 (0.48) | PTGDR2 | |
| SCHEMBL2175029 | 0.79 | LMNA (0.43) | PLA2G2ALMNAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2791111-B1 | [4-(PIPERIDIN-4-YL)-NAPHTHALEN-2-YL]-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS FOR THE TREATMENT OF RESPIRATORY DISORDERS | HOFFMANN LA ROCHE (CH) | 2017-01-18 | — | — | EP | disclosed |
| US-9000044-B2 | Substituted naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2015-04-07 | — | — | US | disclosed |
| EP-2791111-A1 | PIPERIDINYL NAPHTHYLACETIC ACIDS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-22 | — | — | EP | disclosed |
| US-8642629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2358677-B1 | NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| EP-2358677-B1 | NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| WO-2013127841-A1 | SUBSTITUTED NAPHTHYLACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-09-06 | — | — | WO | disclosed |
| US-20130225588-A1 | SUBSTITUTED NAPHTHYLACETIC ACIDS | HOFFMANN-LA ROCHE INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20100125061-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-05-20 | — | — | US | disclosed |
| US-20100125061-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-05-20 | — | — | US | disclosed |
| US-20100125061-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-05-20 | — | — | US | disclosed |
| WO-2010055004-A1 | NAPHTHYLACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010055004-A1 | NAPHTHYLACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
| US-20100125058-A1 | NAPHTHYLACETIC ACIDS | CHEN LI | 2010-05-20 | — | — | US | disclosed |
| US-20100125058-A1 | NAPHTHYLACETIC ACIDS | CHEN LI | 2010-05-20 | — | — | US | disclosed |
| US-20100125058-A1 | NAPHTHYLACETIC ACIDS | CHEN LI | 2010-05-20 | — | — | US | disclosed |
| WO-2010055006-A1 | NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010055006-A1 | NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125058-A1 | NAPHTHYLACETIC ACIDS | HRH2, HRH1, HRH3 | PTGDR2 49/4885PLA2G2A 646/4885LMNA 1698/4885 |
| US-20100125061-A1 | NAPHTHYLACETIC ACIDS | HRH2, HRH1, HRH3 | PTGDR2 32/4885PLA2G2A 866/4885LMNA 1535/4885 |
| US-20130225588-A1 | SUBSTITUTED NAPHTHYLACETIC ACIDS | HRH2, HRH1, HRH3 | PTGDR2 30/4885PLA2G2A 677/4885LMNA 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.